Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NT5E | P21589 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ENTPD3 | O75355 | 1/20 | 0.40 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.40 |
| ▸ | ENTPD1 | P49961 | 1/20 | 0.40 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | NPEPPS | P55786 | 3/20 | 0.39 |
| ▸ | RGS12 | O14924 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19961910 | 0.93 | LMNA (0.46) | LMNAADORA1NPEPPSCYP3A4ADORA2A | |
| SCHEMBL19961888 | 0.87 | NT5E (0.46) | LMNANT5EADORA1ADORA2A | |
| SCHEMBL19961897 | 0.85 | LMNA (0.43) | LMNANT5EKDM4EMEN1CYP1A2 | |
| SCHEMBL19961912 | 0.80 | NT5E (0.51) | LMNANT5E | |
| SCHEMBL19961874 | 0.80 | PDE2A (0.49) | LMNANT5EADORA1ADORA2A | |
| SCHEMBL889648 | 0.79 | HIF1A (0.49) | ENPP1 | |
| SCHEMBL19949034 | 0.78 | NT5E (0.43) | LMNANT5EKDM4EMEN1CYP1A2 | |
| SCHEMBL18571623 | 0.77 | PI4KA (0.62) | LMNAADORA1NPEPPSADORA2A | |
| SCHEMBL18512601 | 0.76 | PI4KA (0.54) | LMNADOT1LADORA1NPEPPS | |
| SCHEMBL12151645 | 0.76 | SMN1; SMN2 (0.42) | NT5EMEN1KMT2ADOT1LADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072742-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072742-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | LMNA 2684/4885NT5E 1/4885KDM4E 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.